On November 20, 2018 Allergan plc (NYSE: AGN), a leading global pharmaceutical company, reported that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Citi Global Healthcare Conference in New York City (Press release, Allergan, NOV 20, 2018, View Source [SID1234531484]). The presentation will begin at 11:00 a.m. Eastern Time on Thursday, December 6, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed on Allergan’s Investor Relations website at View Source;. The webcast can also be accessed through the following URL: https://www.veracast.com/webca…

An archived version will be available within approximately one hour of the live presentation and can be accessed at the same location for 90 days

On November 20, 2018 OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, reported that Daniel J. O’Connor, President and Chief Executive Officer of OncoSec, will present at the Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018 at 11:30 a.m. ET in New York City (Press release, OncoSec Medical, NOV 20, 2018, View Source [SID1234531500]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Investors section of OncoSec’s website at ir.oncosec.com, where it will be archived for approximately 30 days

On November 20, 2018 GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on innovative treatments based on the Company’s proprietary NK-engager and Bispecific Antibody Drug Conjugate platforms, reported that its abstracts have been selected for presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting being held December 1-4, 2018 in San Diego, CA (Press release, GT Biopharma , NOV 20, 2018, View Source [SID1234539519]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Summarized below are the abstract titles that have been selected for oral and poster presentations. The ASH (Free ASH Whitepaper) abstracts are now available online at the conference website, here.

Saturday, December 1, 2018

Session: 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster I
Time: 6:15 PM-8:15 PM PT
Presenter: Upasana Sunil Arvindam, MSc, BSc, Department of Microbiology and Immunology, University of Minnesota, Minneapolis, MN
Abstract #1454: CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia

Monday, December 3, 2018

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, Including HIV and Other Infections: Pre-Clinical T and NK Cell Immunotherapies
Time: 3:15 PM PT
Presenter: Emily Chiu, PhD, Medical School, University of Minnesota, Minneapolis, MN
Abstract #729: Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

On November 20, 2018 Array BioPharma Inc. (Nasdaq: ARRY) reported that its Chief Executive Officer, Ron Squarer, will speak at the 30th Annual Piper Jaffray Healthcare Conference in New York (Press release, Array BioPharma, NOV 20, 2018, View Source [SID1234531485]). The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:

30th Annual Piper Jaffray Healthcare Conference

Presenter:

Ron Squarer, Chief Executive Officer, Array BioPharma

Date:

Tuesday, November 27, 2018

Time:

9:00 a.m. Eastern Time

Webcast:

View Source;tp_key=8e5fb74efb

On November 20, 2018 Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, reported that it will participate in a fireside chat at the Evercore ISI HealthconX Conference in Boston, MA on Tuesday, November 27 (Press release, Aeglea BioTherapeutics, NOV 20, 2018, http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-present-evercore-isi-healthconx [SID1234531501]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Date: Tuesday, November 27, 2018
Time: 2:45 p.m. ET
Location: The Boston Harbor Hotel, Boston, MA
Room: South Atlantic Room (2nd floor)
Webcast: View Source

To access the live and archived audio webcast of the fireside chat, visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. Replays of the webcast will be available for 30 days thereafter.